0000000000745213

AUTHOR

Josep Nomdedeu

0000-0003-3399-346x

showing 2 related works from this author

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

2018

© 2018 by the authors.

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNPM1PTK2acute myeloid leukemialcsh:RC254-282Article03 medical and health sciences0302 clinical medicinePTK2BLYNInternal medicinehemic and lymphatic diseasesmedicineLYNprognostic factorPrognostic factorintermediate-riskPTK2BAcute myeloid leukemiaPTK2business.industryMyeloid leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCohortIntermediate-riskbusinessTyrosine kinaseProto-oncogene tyrosine-protein kinase SrcCancers
researchProduct

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

2020

Abstract The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations. At a median follow-up of 60.7 months (95% CI, 55.0-70.8), the 5-year event-free survival (EFS) rate was significantly higher in patients treated with midostaurin than in those treated with placebo (45.2% vs 30.1%; P = .044). A trend toward improved …

Oncologymedicine.medical_specialtyNPM1Myeloidmedicine.medical_treatmentCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Context (language use)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterInternal medicinehemic and lymphatic diseasesmedicineHumansMidostaurinChemotherapyMyeloid Neoplasiabusiness.industryMyeloid leukemiaHematologyStaurosporineSettore MED/15medicine.diseaseTransplantationLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structurefms-Like Tyrosine Kinase 3chemistry030220 oncology & carcinogenesisMutationbusinessNucleophosmin030215 immunology
researchProduct